Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
m-BEACOPP
- Development stage
- Phase 3
- Lead developer
- German Hodgkin Study Group
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
m-BEACOPP is a modified version of the BEACOPP chemotherapy regimen, which is a combination of drugs used primarily for the treatment of advanced or unfavorable Hodgkin lymphoma. The standard BEACOPP regimen includes bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone (or prednisolone). The "m" in m-BEACOPP typically refers to a modification in dosing or scheduling compared to the original protocol. These modifications are intended to reduce toxicity while maintaining efficacy. The drugs in this regimen work by targeting rapidly dividing cells such as cancer cells; most are cytotoxic chemotherapy agents except for prednisone/prednisolone, which is a steroid that helps control inflammation and immune responses.
- Other names
- modified BEACOPPmodified bleomycin etoposide doxorubicin cyclophosphamide vincristine procarbazine prednisone
02
Targets
DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on m-BEACOPP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on m-BEACOPP.